Latanoprost intratympanic - Synphora

Drug Profile

Latanoprost intratympanic - Synphora

Alternative Names: JB-004

Latest Information Update: 04 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Synphora
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Meniere's disease; Tinnitus

Highest Development Phases

  • Phase II/III Meniere's disease

Most Recent Events

  • 04 May 2017 Phase-II/III development for Meniere's disease is ongoing in Sweden (Intratympanic) (Synphora website, May 2017)
  • 23 May 2016 Synphora completes a phase II/III trial for Meniere's disease in Sweden (Intratympanic) (EudraCT2013-002261-18; NCT01973114)
  • 24 Feb 2016 Latanoprost intratympanic is available for licensing as of 24 Feb 2016. http://www.synphora.com/partnering.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top